Special Issue "Access to Cancer Drugs in Canada"
A special issue of Current Oncology (ISSN 1718-7729).
Deadline for manuscript submissions: 31 December 2021.
The therapeutic landscape in cancer has been changing rapidly for a century now since the emergence of radiotherapy in the early 1900s, and chemotherapy a few decades later. However, it seems as though the pace of progress has continued to accelerate as we rapidly have entered the era of novel chemotherapies and combinations, monoclonal antibodies, targeted therapies, immune checkpoint inhibitors, drug-antibody conjugates and more.
The regulatory processes in place to deal with the increasing numbers of effective drugs naturally needs to develop and progress too, reflecting and balancing the efficacies of new therapies, their place in treatment algorithms, the potential high price and cost-effectiveness, and the more nuanced discussions around value.
In this Special Issue of Current Oncology, manuscripts are invited to reflect on or educate about the challenges of the Canadian regulatory system, ranging from Health Canada, the Patented Medicines Prices Review Board (PMPRB), the Canadian Agency for Drugs and Technologies in Health (CADTH), who oversee the health technology assessment (HTA) and Reimbursement Reviews (formerly pan-Canadian Oncology Drug Review, or pCODR), to the pan Canadian Pharmaceutical Alliance (PCPA) that recommends a price to the territories and provinces.
These multiple steps in the regulatory process are changing, and often poorly understood by rank and file clinicians. This issue will seek to educate readers, and discuss the implications of change, the international context that Canada works in, the role of physicians as advocates or adjudicators, the pros and cons of a potential national pharmacare system, and debates around cost and value.
Manuscripts are invited that address these issues, or other issues that are considered relevant to the Special Issue title ‘Access to cancer drugs in Canada’.
Dr. Paul Wheatley-Price
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.